Hikal (524735) Aktienübersicht
Hikal Limited produziert und verkauft zusammen mit seinen Tochtergesellschaften verschiedene chemische Zwischenprodukte, Spezialchemikalien und pharmazeutische Wirkstoffe an Pharma-, Tiergesundheits-, Biotech-, Pflanzenschutz- und Spezialchemieunternehmen in Indien, den Vereinigten Staaten, Kanada, Europa, Südostasien und auf internationaler Ebene. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 1/6 |
524735 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hikal Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹244.75 |
| 52-Wochen-Hoch | ₹355.00 |
| 52-Wochen-Tief | ₹145.95 |
| Beta | 0.56 |
| 1 Monat Veränderung | 33.05% |
| 3 Monate Veränderung | 33.67% |
| 1 Jahr Veränderung | -28.16% |
| 3 Jahre Veränderung | -18.74% |
| 5 Jahre Veränderung | -52.81% |
| Veränderung seit IPO | 23,843.01% |
Aktuelle Nachrichten und Updates
524735: Dividend And Board Changes Will Support Future Upside Potential
Analysts have trimmed their price target for Hikal from ₹320 to ₹300, reflecting updated assumptions for slightly lower revenue growth, a softer profit margin outlook, and a higher future P/E multiple. What’s in the News for Hikal Hikal has scheduled a Special or Extraordinary Shareholders Meeting on July 4, 2026, to be conducted via postal ballot in India.524735: Board Actions And Dividend Decision Will Support Future Upside Potential
Analysts have kept Hikal's fair value unchanged at ₹320.0 while adjusting underlying assumptions, including a slightly higher discount rate, revised revenue growth and profit margin inputs, and a lower future P/E, which together shape the refreshed price target narrative. What's in the News A board meeting is scheduled for May 27, 2026, at 11:00 IST to review and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.524735: Interim Dividend And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320, reflecting unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend on equity shares for FY 2025-26 (company filing).Recent updates
524735: Dividend And Board Changes Will Support Future Upside Potential
Analysts have trimmed their price target for Hikal from ₹320 to ₹300, reflecting updated assumptions for slightly lower revenue growth, a softer profit margin outlook, and a higher future P/E multiple. What’s in the News for Hikal Hikal has scheduled a Special or Extraordinary Shareholders Meeting on July 4, 2026, to be conducted via postal ballot in India.524735: Board Actions And Dividend Decision Will Support Future Upside Potential
Analysts have kept Hikal's fair value unchanged at ₹320.0 while adjusting underlying assumptions, including a slightly higher discount rate, revised revenue growth and profit margin inputs, and a lower future P/E, which together shape the refreshed price target narrative. What's in the News A board meeting is scheduled for May 27, 2026, at 11:00 IST to review and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.524735: Interim Dividend And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320, reflecting unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend on equity shares for FY 2025-26 (company filing).524735: Interim Dividend And Steady Assumptions Will Support Bullish Upside Potential
Analysts have maintained their fair value estimate for Hikal at ₹320, citing essentially unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E. This keeps their overall price target view steady.524735: Interim Dividend And Stable Assumptions Will Support Bullish Upside Potential
Analysts have kept their fair value estimate for Hikal broadly unchanged at around ₹320, reflecting largely steady assumptions on discount rate, revenue growth, profit margin and future P/E, and signaling no meaningful shift in their overall view of the stock. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).524735: Interim Dividend And Stable Outlook Will Support Bullish Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320. This points to largely unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiple in their latest price target update.524735: Interim Dividend And Upcoming Results Will Support Bullish Upside Potential
Analysts have kept their price target on Hikal unchanged at ₹320, reflecting broadly steady views on revenue growth, margins and fair value, with only a small adjustment to the assumed future P/E multiple. What's in the News The Board will meet on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend for FY 2025-26 (company filing).524735: Upcoming Results And Interim Dividend Decision Will Support Future Upside
Analysts have lifted their price target on Hikal to ₹320, reflecting updated assumptions around a lower discount rate, faster revenue growth, a slimmer profit margin, and a higher future P/E multiple. What's in the News Board meeting scheduled on Feb 11, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).524735: Stable Margins And Upcoming Results Will Support Future Dividend Upside
Analysts have kept their fair value estimate for Hikal steady at ₹320.0 per share. This reflects unchanged views on growth, margins, discount rate, and future P/E assumptions used in their price target work.524735: Profitability Will Improve As Stable Margins Support Future Dividend Upside
Analysts have modestly reiterated their outlook on Hikal, keeping the average 12 month price target broadly stable around ₹320 per share, as unchanged growth, margin, and valuation assumptions continue to support a steady fair value profile. What's in the News Board meeting scheduled for November 13, 2025, to review and approve standalone and consolidated unaudited financial results for Q2 and H1 FY2025 (company filing) Shareholders at the 37th AGM on September 23, 2025, approved a final dividend of INR 0.80 per equity share of INR 2, taking the total FY2024-25 dividend to INR 1.40 per share (AGM resolution) Valuation Changes Fair Value: Unchanged at approximately ₹320 per share, indicating a stable assessment of intrinsic value.524735: Profitability Will Improve As Margins Recover And Regulatory Risks Fade
Analysts have raised their price target for Hikal to ₹320.00, citing improved forecasts for revenue growth and profit margin in addition to a stronger outlook for future profitability. What's in the News A board meeting is scheduled for November 13, 2025, to approve unaudited financial results for the second quarter and half year ended September 30, 2025 (Key Developments).524735: Future Margins Will Recover Following Regulatory Facility Improvements
Narrative Update: Hikal Analyst Price Target Adjustment Analysts have decreased their fair value estimate for Hikal from ₹390 to ₹320 due to revised expectations for revenue decline and lower profit margins. What's in the News The United States FDA issued a warning letter to Hikal's drug manufacturing facility in Karnataka following an inspection in February 2025.Global Supply Chain Diversification Will Unlock Indian CRAMS Potential
As both net profit margin and consensus revenue growth forecasts for Hikal remained stable, analysts have maintained their fair value estimate with the price target unchanged at ₹390.00. What's in the News Hikal's Board of Directors will meet to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2025.
New Panoli Facility And Global Expansions Will Strengthen Operations Over Next 2-3 Years
Strategic focus on operating leverage and product mix is set to improve net margins and revenue diversification.Aktionärsrenditen
| 524735 | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 10.1% | 0.7% | 0.3% |
| 1Y | -28.2% | 13.8% | -0.09% |
Rendite im Vergleich zur Industrie: 524735 unter dem Niveau der Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 13.8% erzielte.
Rendite vs. Markt: 524735 hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von -0.1 erzielte.
Preisvolatilität
| 524735 volatility | |
|---|---|
| 524735 Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.9% |
Stabiler Aktienkurs: 524735 hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 524735Die wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1988 | 2,062 | Sameer Hiremath | www.hikal.com |
Hikal Limited produziert und verkauft zusammen mit seinen Tochtergesellschaften verschiedene chemische Zwischenprodukte, Spezialchemikalien und pharmazeutische Wirkstoffe an Pharma-, Tiergesundheits-, Biotech-, Pflanzenschutz- und Spezialchemieunternehmen in Indien, den USA, Kanada, Europa, Südostasien und auf internationaler Ebene. Das Unternehmen ist in zwei Segmenten tätig: Pharmazeutika und Pflanzenschutz. Das Segment Pharmazeutika stellt pharmazeutische Wirkstoffe (APIs) her.
Hikal Limited's Grundlagenzusammenfassung
| 524735 grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹30.18b |
| Gewinn(TTM) | -₹488.00m |
| Umsatz(TTM) | ₹17.13b |
Ist 524735 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 524735 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹17.13b |
| Kosten der Einnahmen | ₹7.62b |
| Bruttogewinn | ₹9.51b |
| Sonstige Ausgaben | ₹10.00b |
| Gewinn | -₹488.00m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -3.96 |
| Bruttomarge | 55.52% |
| Nettogewinnspanne | -2.85% |
| Schulden/Eigenkapital-Verhältnis | 56.8% |
Wie hat sich 524735 auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/12 22:22 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Hikal Limited wird von 2 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Kameswari V. S. Chavali | FirstCall Research |